JPA Prize in 2014
JPA Prize Medal
Bart De Spiegeleer
Department of Pharmaceutical Analysis Drug Quality & Registration group Ghent University Belgium
1.Stacy Brown
Pharmaceutical Sciences East Tennessee State University United States of America
2.Satyanarayanaraju Sagi
School of Pharmacy National Center for Natural Products Research University of Mississippi United States of America
1. Joseph J. Kirkland, Stephanie A. Schuster*, William L. Johnson, Barry E. Boyes. Fused-core particle technology in high-performance liquid chromatography: An overview. Journal of Pharmaceutical Analysis, 2013, 3(5): 303-312.
Fig. 2 Separation of anticoagulants with fused-core columns of different selectivities. Columns: 50 mm × 4.6 mm Halo C18, 50 mm × 4.6 mm Halo RP-amide, 50 mm × 4.6 mm Halo phenyl–hexyl; mobile phase: A/B = 40/60; A = 0.1% formic acid, pH 2.6; B = methanol/acetonitrile, 50/50; flowrate: 2.0 mL/min; temperature: 45 ºC; pressure: 210 bar; detector, UV: 254 nm; 1 μL injection; andsolutes: (1) uracil, (2) 4-hydroxycoumarin, (3) coumarin, (4) 6-chloro-4-hydroxycoumarin, (5) warfarin, (6) coumatetralyl, and (7) coumachlor, i = impurity.
2. Srinivasa Rao Polagani, Nageswara Rao Pilli, Ramakrishna Gajula, Venkateswarlu Gandu*. Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Journal of Pharmaceutical Analysis, 2013, 3(1): 9-19.
3. T. Satyanarayana Raju*, O. Vishweshwari Kutty, V. Ganesh, P. Yadagiri Swamy. A validated stabilityindicating LC method for the separation of enantiomer and potential impurities of Linezolid using polar organic mode. Journal of Pharmaceutical Analysis, 2012, 2(4): 272-278.
Fig. 3 Complete degradation profile of Linezolid along with the % impurity formation and corresponding mass nos. of impurities.
Journal of Pharmaceutical Analysis2015年5期